-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
| Nebulized inhalation of Mycobacterium vaccae vaccine may shorten the time for new coronary pneumonia nucleic acid to become negative |
Science and Technology Daily, Nanning, April 5th (Reporter Liu Hao) On the 5th, the reporter learned from Guangxi Medical University that the team of Professor Li Chaoqian of the school carried out "Aerosolized Inhalation of Mycobacterium vaccae Vaccine in the Treatment of COVID-19 Clinical Study-A Randomized Study" The "double-blind controlled experiment" study showed that the technology can shorten the time for nucleic acid to become negative, and there is no severe disease, reyang and obvious adverse reactions.
Severe Acute Respiratory Syndrome Type 2 Coronavirus is highly contagious, and there is currently no specific treatment.
According to the research team members, the selected cases were randomly divided into 2 groups: group A (conventional treatment group) and group B (mycobacterium vaccae vaccine combined with conventional treatment group).
Professor Li Chaoqian’s team has been engaged in respiratory mucosal immunity research for many years.
"The team's series of basic, animal and clinical research results show that the new technology and theoretical research results are expected to provide new ways and theoretical basis for clinical non-specific early prevention and treatment of respiratory virus infections.
aspx?id=3570" target="_blank" style="color:#ba1413">Focus on the new crown pneumonia epidemic
